In a year made difficult by the COVID-19 pandemic, the health and life sciences sector in Catalonia reached an exceptional milestone. In 2020, startups in the BioRegion managed to raise €226 million in investment, the most ever, doubling in just two years from €112 million in 2018.
The main source of this funding was venture capital, with a total of €140 million. There were 41 operations in total, up 58% from 2019. This data is from the final version of the “Investment in startups” chapter of the BioRegion of Catalonia Life Sciences and Healthcare Outlook 2020 - Challenges Ahead, presented this morning by Biocat and CataloniaBio & HealthTech after being updated to give a more complete view than the version presented in September 2020.
Although the biggest operations are mostly in biotech and medtech, digital health companies grew the fastest, with investment multiplying by a factor of 2.6 since 2018.
As Biocat CEO Jordi Naval highlighted, these indicators show that “the figures reinforce our belief in the potential for scaling up the ecosystem to the level seen in other European countries. There is no reason we can’t be ambitious and think that we’ll see similar investment figures and aspire to attract series A.”
In addition to the updated funding and investment figures, the report also features macroeconomic and innovation indicators for the healthcare and life sciences sector in Catalonia and discusses the challenges and vision for the BioRegion of Catalonia over the coming years. In fact, the life sciences and healthcare sector employs 230,000 people and accounts for 7.3% of the Catalan GDP.
Exponential growth in international investment
International investors were present in 4 out of 10 rounds of funding, or 62.2% of all venture capital raised. The number of international investors also increased five-fold, from 14 in 2015 to 73 in 2020. Most of them are from Europe (42) and the United States (22).
In this regard, Judit Anido, CEO of CataloniaBio & HealthTech, points out that “the steady growth in international investment confirms the quality of pipelines, business models and teams at Catalan startups, as well as the fact that they are competitive on the global market.”
Last year, seven companies raised over €10 million in investment. Biotechnology companies are at the top of the list, with a record investment of €142.6 million, fuelled by three large operations that made up nearly half the total raised: Ona Therapeutics (€30 million), Minoryx Therapeutics (€25 million) and Oryzon (€20 million).
Catalan representation at Bio-Europe Spring®
The presentation of investment data for Catalan startups coincides with the inauguration of the 15th annual BIO-Europe Spring®, one of the main events for biotech and pharmaceutical industries and finance specialising in the health and life sciences in Europe.
The event, which was scheduled to be held in Barcelona for the fourth time (2010, 2013 and 2017), will be fully virtual, on 25 March, due to the pandemic. Catalonia has a strong presence, accounting for 65% of the Spanish delegation.
In fact, by collaborating with the fair as a Platinum Sponsor, Biocat and CataloniaBio & HealthTech, along with ACCIÓ have enabled professionals from the BioRegion to participate under advantageous conditions. In this sense, the lecture program features one session that seeks to bring visibility to the startups potential in the ecosystem with a panel discussion highlighting this year’s three biggest success stories: Ona Therapeutics, Neuroelectrics and Koa Health.
De fet, la col·laboració de Biocat, CataloniaBio & HealthTech i ACCIÓ amb l’organització com a Platinum Sponsors, ha facilitat la participació de professionals de la BioRegió amb condicions avantatjoses. En aquest sentit, el programa de conferències compta amb la sessió Investment success stories that make Catalonia the healthcare innovation hotspot of Europe per visibilitzar el potencial de les startups amb tres històries d’èxit d’enguany: Ona Therapeutics, Neuroelectrics i Koa Health.
Related information:
Comments